Stock Market Today, Feb. 25: Novo Nordisk Dips After Announcing $2.1 Billion Partnership With Vivtex for Oral Drug-Delivery Technologies
The Motley Fool
by newsfeedback@fool.com (Josh Kohn-Lindquist)February 25, 2026
AI-Generated Deep Dive Summary
Novo Nordisk (NYSE:NVO), a leading developer of diabetes and obesity treatments, saw its stock dip by 1.11% to close at $38.16 on February 25th. This decline was attributed to investor concerns over the company's newly announced $2.1 billion partnership with Vivtex for oral drug-delivery technologies. Additionally, traders considered the impact of steep price cuts for key medications like Wegovy and Ozempic, which were revealed earlier in the week. The trading volume surged to 54.7 million shares, significantly higher than its three-month average, reflecting heightened investor interest and potential unease.
The partnership with Vivtex aims to enhance Novo Nordisk's oral-drug delivery capabilities, a critical area given the increasing competition in the pharmaceutical sector. Earlier in the week, the company had announced a 35% to 50% price reduction for its popular medications, effective January 1, 2027. This move was seen as an attempt to retain market share against rival Eli Lilly, whose new obesity drug outperformed Novo's CagriSema in a Phase 3 trial. Consequently, Novo Nordisk faced a 15% stock drop on Monday, and over the last five business days, its shares had fallen by 20%, indicating investor skepticism about the company's strategic decisions.
The broader market showed resilience despite these developments, with the S&P 500 gaining 0.82% to close at 6,947 and the Nasdaq Composite rising 1.26% to finish at 23,152. However, within the pharmaceutical sector, reactions were mixed: Eli Lilly saw a 1.28% decline, while Novartis dropped by 0.1
Verticals
financeinvesting
Originally published on The Motley Fool on 2/25/2026